PMID- 16525632
OWN - NLM
STAT- MEDLINE
DCOM- 20060606
LR  - 20181201
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 28
IP  - 4
DP  - 2006 Apr
TI  - Survivin associates with cell proliferation in renal cancer cells: regulation of 
      survivin expression by insulin-like growth factor-1, interferon-gamma and a novel 
      NF-kappaB inhibitor.
PG  - 841-6
AB  - Although survivin has been widely recognized as an attractive target for cancer 
      therapy, the exact mechanism regarding the regulation of survivin and its effect 
      on cell proliferation have yet to be clearly defined in renal cell carcinoma 
      (RCC). We investigated herein the association between survivin expression and 
      cell proliferation in a RCC cell line, KU19-20. In KU19-20 cells, cell 
      proliferation and survivin expression were significantly induced by IGF-1, 
      whereas they were inhibited by a novel NF-kappaB inhibitor 
      dehydroxymethyl-epoxyquinomicin (DHMEQ) and IFN-gamma. The combination of DHMEQ 
      and IFN-gamma inhibited cell proliferation synergistically with a pronounced 
      attenuation of survivin expression. Furthermore, treatment with survivin-specific 
      siRNA reduced expression of survivin and significantly inhibited cell 
      proliferation. Survivin expression was thus associated with cell proliferation in 
      KU19-20 cells. The regulation of survivin by IFN-gamma and/or an NF-kappaB 
      inhibitor may therefore be a potential treatment modality for RCC.
FAU - Sato, Akinori
AU  - Sato A
AD  - Department of Urology, School of Medicine, Keio University, Tokyo 160-8582, 
      Japan.
FAU - Oya, Mototsugu
AU  - Oya M
FAU - Ito, Keiichi
AU  - Ito K
FAU - Mizuno, Ryuichi
AU  - Mizuno R
FAU - Horiguchi, Yutaka
AU  - Horiguchi Y
FAU - Umezawa, Kazuo
AU  - Umezawa K
FAU - Hayakawa, Masamichi
AU  - Hayakawa M
FAU - Murai, Masaru
AU  - Murai M
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Benzamides)
RN  - 0 (Cyclohexanones)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0 (NF-kappa B)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Survivin)
RN  - 0 (dehydroxymethylepoxyquinomicin)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Benzamides/pharmacology
MH  - Carcinoma, Renal Cell/genetics/pathology/physiopathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/*drug effects
MH  - Cyclohexanones/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Synergism
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins
MH  - Insulin-Like Growth Factor I/pharmacology
MH  - Interferon-gamma/pharmacology
MH  - Kidney Neoplasms/genetics/pathology/physiopathology
MH  - Microtubule-Associated Proteins/*genetics/physiology
MH  - NF-kappa B/antagonists & inhibitors
MH  - Neoplasm Proteins/*genetics/physiology
MH  - RNA Interference/physiology
MH  - RNA, Small Interfering/genetics
MH  - Survivin
MH  - Transfection
EDAT- 2006/03/10 09:00
MHDA- 2006/06/07 09:00
CRDT- 2006/03/10 09:00
PHST- 2006/03/10 09:00 [pubmed]
PHST- 2006/06/07 09:00 [medline]
PHST- 2006/03/10 09:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2006 Apr;28(4):841-6.